Floatz Rating
CCC50/100
Confidence
Indicative
Sponsor
Actuate Therapeutics Inc.
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
35Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03678883CT.gov 9-ING-41 in Patients With Advanced Cancers | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Carcinoma In The Bone
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Elraglusib (this asset) | Actuate Therapeutics Inc. | P2 | CCC · 50 |
| Denosumab | Kelly Fitzgerald, MD | P4 | BBB |
| Zoledronate | Kelly Fitzgerald, MD | P4 | BBB |
| Ibandronate | Kelly Fitzgerald, MD | P4 | BBB |
| Radium Ra-223 | University of California, San Francisco | P3 | BB |
| Zometa | Sun Yat-sen University | P4 | BB |
| Technetium Tc-99M Cation, Unspecified | University of California, San Francisco | P3 | BB |
| Dentalfluoro | HTA Co., Ltd. | P3 | BB |
| Cabozantinib | National Cancer Institute (NCI) | P3 | BB |
+42 more in the Metastatic Carcinoma In The Bone cohort
Other indications for Elraglusib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neoplasm | — | P2 | CCC · 54 |
| Refractory Malignant Neoplasm | — | P2 | CCC · 52 |
| Bone Cancer | — | P2 | CCC · 50 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Elraglusib in Metastatic Carcinoma In The Bone. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/elraglusib-metastatic-carcinoma-in-the-bone
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →